Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
1 Year : From Oct 2018 to Oct 2019
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Peter S.
Carbone has joined the Company as Senior Vice President, Quality. Mr.
Carbone will report to Ron Cohen, M.D., President and CEO of Acorda and
will be a member of the Company’s Leadership Team.
In his role, Mr. Carbone will lead Acorda’s Quality Assurance and
Quality Control departments and manage all company-wide quality
initiatives, including the Quality Management System. In addition, he
will develop and maintain quality programs to ensure Acorda’s compliance
with guidelines of the U.S. Food and Drug Administration (FDA) and other
world-wide health authorities. Mr. Carbone will manage teams in Acorda’s
Ardsley, New York headquarters and its Boston, Massachusetts
manufacturing and development facilities.
“Peter brings to Acorda over 30 years of pharmaceutical and industry
experience in engineering, quality and technical management,” said Dr.
Cohen, “We are delighted to welcome him to our leadership team. One of
our top priorities is to continue to the build upon the strong track
record of success of our quality teams as we manufacture and
commercialize INBRIJA and develop other products in our pipeline.
Peter’s leadership will be critical to these efforts.”
Before joining Acorda, Mr. Carbone was the Vice President of Quality
Solids Americas & Special Technologies at Novartis, responsible for the
oversight of eight manufacturing facilities in North and South America
and Europe, and for commercial Quality for all Sandoz products
distributed in the US.
“I am very excited to be joining Acorda. The approval of INBRIJA is an
important milestone for the Company and for patients, and I look forward
to partnering with the Company’s Quality teams to maintain and build on
the excellent systems they have developed,” said Carbone.
Prior to joining Novartis, Mr. Carbone spent over two decades in a
variety of roles of increasing seniority at a number of pharmaceutical
companies, including Allergan, where he was the Vice President of
Biologics Quality, and Amgen, where he was the Executive Director of
Corporate Quality-Validation. He has a B.S. in Chemical Engineering from
Rensselaer Polytechnic Institute. He is a previous member of the ISPE
International Board of Directors, the ISPE Quality Metrics Steering
Committee and PhRMA GQMC.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and improve
the lives of people with neurological disorders. INBRIJA™ (levodopa
inhalation powder) is approved for intermittent treatment of OFF
episodes in patients with Parkinson’s treated with carbidopa/levodopa.
INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary
delivery system, a technology platform designed to deliver medication
through inhalation. Acorda also markets the branded AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg.
This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management's
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: we may
not be able to successfully market Inbrija or any other products under
development; risks associated with complex, regulated manufacturing
processes for pharmaceuticals, which could affect whether we have
sufficient commercial supply of Inbrija to meet market demand; third
party payers (including governmental agencies) may not reimburse for the
use of Inbrija or our other products at acceptable rates or at all and
may impose restrictive prior authorization requirements that limit or
block prescriptions; competition for Inbrija, Ampyra and other products
we may develop and market in the future, including increasing
competition and accompanying loss of revenues in the U.S. from generic
versions of Ampyra (dalfampridine) following our loss of patent
exclusivity; the ability to realize the benefits anticipated from
acquisitions, among other reasons because acquired development programs
are generally subject to all the risks inherent in the drug development
process and our knowledge of the risks specifically relevant to acquired
programs generally improves over time; we may need to raise additional
funds to finance our operations and may not be able to do so on
acceptable terms; the risk of unfavorable results from future studies of
Inbrija (levodopa inhalation powder) or from our other research and
development programs, or any other acquired or in-licensed programs ;
the occurrence of adverse safety events with our products; the outcome
(by judgment or settlement) and costs of legal, administrative or
regulatory proceedings, investigations or inspections, including,
without limitation, collective, representative or class action
litigation; failure to protect our intellectual property, to defend
against the intellectual property claims of others or to obtain third
party intellectual property licenses needed for the commercialization of
our products; and failure to comply with regulatory requirements could
result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this press release are made only as
of the date hereof, and we disclaim any intent or obligation to update
any forward-looking statements as a result of developments occurring
after the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190204005199/en/
MEDIA:Gail Cohen(914) firstname.lastname@example.org
INVESTOR RELATIONS:Felicia Vonella(914) email@example.com